武田製藥：總體而言，89.4％的患者報告了不良事件。與Hyqvia有關的AES在60％的患

快訊 · 06/18 20:03

Takeda Pharmaceutical: Overall, Adverse Events Were Reported in 89.4% of Patients. AES Related to Hyqvia Were Reported in 60% of Patients

武田製藥：總體而言，89.4％的患者報告了不良事件。與Hyqvia有關的AES在60％的患者中報告。